Australia, July 7 -- Tubulis Gmbh, owns the trademark (2530022) for 'Tubutecan' till Feb. 6, 2035.

Status: protected: Registered/protected

Classes: 1 [Chemical, biochemical, biological, and biotechnological preparations, in particular, antibodies, fragments of antibodies and antibody-drug conjugates for industrial and scientific use; antibodies, fragments of antibodies and antibody-drug conjugates for the development or manufacture of therapeutic reagents for industrial and scientific use; biological preparations, in particular, antibodies, fragments of antibodies and antibody-drug conjugates for laboratories, diagnostics and analytics for scientific or research use; chemical, biochemical, biological, and biotechnological preparations for industrial and scientific use.], 5 [Pharmaceutical and veterinary preparations and substances for the treatment of cancer, inflammatory diseases, autoimmune diseases, infective diseases, cardiovascular diseases, liver metabolic disorders and other conditions which can be treated or ameliorated by antibodies binding to, or activation or blocking of, a target antigen; antibody-drug conjugates; pharmaceutical and veterinary preparations comprising small molecules; small molecule compounds for treatment of cancer; all of the forgoing containing topoisomerase I inhibitor antineoplastics] and 42 [Scientific services and research relating thereto in the fields of biology, chemistry or medicine, as well as in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and/or medicinal chemistry as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and/or diagnostic apparatus.]

Type of Mark: Word

Date of Acceptance: April 27

Registration Advertised: July 6

For further details contact Oxygene IP and df-mp Patentanwalte Rechtsanwalte PartG mbB.

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2530022.

Disclaimer: Curated by HT Syndication.